Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Bolt Biotherapeutics (BOLT) FCF Margin (2020 - 2025)

Bolt Biotherapeutics' FCF Margin history spans 6 years, with the latest figure at 452.01% for Q3 2025.

  • For Q3 2025, FCF Margin rose 77236.0% year-over-year to 452.01%; the TTM value through Sep 2025 reached 907.7%, down 28217.0%, while the annual FY2024 figure was 797.0%, 8836.0% up from the prior year.
  • FCF Margin for Q3 2025 was 452.01% at Bolt Biotherapeutics, up from 531.98% in the prior quarter.
  • Across five years, FCF Margin topped out at 317.61% in Q1 2024 and bottomed at 3846.65% in Q4 2021.
  • The 5-year median for FCF Margin is 1159.03% (2024), against an average of 1333.44%.
  • The largest annual shift saw FCF Margin soared 256132bps in 2022 before it plummeted -77608bps in 2025.
  • A 5-year view of FCF Margin shows it stood at 3846.65% in 2021, then skyrocketed by 67bps to 1285.33% in 2022, then skyrocketed by 47bps to 683.15% in 2023, then plummeted by -79bps to 1224.36% in 2024, then soared by 63bps to 452.01% in 2025.
  • Per Business Quant, the three most recent readings for BOLT's FCF Margin are 452.01% (Q3 2025), 531.98% (Q2 2025), and 1093.7% (Q1 2025).